The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
about
5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstructionNew therapeutic strategies for the treatment of male lower urinary tract symptomsKorean clinical practice guideline for benign prostatic hyperplasiaFixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasiaPhosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive reviewCombination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focusThe pathophysiology of delayed ejaculationCurrent status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.Bloodless management of benign prostatic hyperplasia: medical and minimally invasive treatment options.The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (ComThe economic impact of delaying 5-alpha reductase inhibitor therapy in men receiving treatment for symptomatic benign prostatic hyperplasia.Initial treatment of men with newly diagnosed lower urinary tract dysfunction in the Veterans Health AdministrationPersonalized medicine for the management of benign prostatic hyperplasiaExpression of apoptosis-regulating genes in the rat prostate following botulinum toxin type A injection.Chemoprevention of prostate cancer.Benign prostatic hyperplasia: from bench to clinicDutasteride for the treatment of prostate-related conditions.Role of 5α-reductase inhibitors in benign prostatic diseases.Dutasteride for the treatment of benign prostatic hyperplasia.Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year rSilodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscleThe feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis.Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis.Dutasteride plus tamsulosin fixed-dose combination first-line therapy versus tamsulosin monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting.Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor SyndromePatient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis.Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia.Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia.Management of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia by general practitioners in JakartaLower urinary tract symptoms in men.Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability.Late-onset hypogonadism syndrome and lower urinary tract symptoms.Effects of preoperative dutasteride treatment in holmium laser enucleation of the prostate.Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat.Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?Changing patients' profile presenting for surgical management of benign prostatic hyperplasia over the past 16 years: A single-centre perspectiveEstablishment of Reference Ranges for Prostate Volume and Annual Prostate Volume Change Rate in Korean Adult Men: Analyses of a Nationwide Screening Population.Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model.
P2860
Q24188312-3E449BED-B1CD-4646-8237-83E35D84CA81Q26746138-012D51E5-A3C0-4135-9108-6547BCDA75DBQ26766302-B1CE68EF-069F-4F69-A637-CC1A584FA7D6Q26770425-B4D763C6-9A94-43B3-A724-A578B17441BEQ26785752-6C095C3F-A9F1-4C47-8E0E-4A1D01DC709EQ27008847-40D9F241-83FC-4249-B07A-3E55E1A1B0CBQ28074466-F30F7008-819A-4EE7-A817-ABE4F1B45046Q33602452-C591F45D-AB25-4FC5-B5D1-C013519748F8Q33797223-A4FAF0BA-1DE6-407F-AECB-E008421C0033Q33829176-15E2709E-6F63-499D-B028-62B1B7DE3E37Q33928886-0244CD82-2392-4266-AB04-22E471EECC1CQ33959807-59A5BE92-CFA4-4E14-90B4-DAAEAF6B7069Q34084593-089E4068-76E8-4E30-9609-0C52224F5790Q34118150-3052E6C6-34F9-4C70-A4A9-156907D93D89Q34186757-50B00510-6B55-435D-9AAF-47178C5D5941Q34216723-64BD101F-C117-4A13-9903-3B32C318F192Q34252953-2DD46180-1B45-47D7-90E2-9D98D0C5D01CQ34254296-D07B4049-D159-438E-B491-0B6BC9AC57CCQ34349726-37E8D594-840B-4B9F-AA20-DB3410EF787CQ34377799-6612A645-B64A-4883-B8A1-50460E6FB19DQ34506119-D2D081CB-8DF8-4864-9B30-3E5323DDD1AFQ34522113-1DD53F1A-6009-446B-8EF1-2569214B1C22Q34531114-12139DC5-E3A1-4C1B-B7B7-243A296CAB68Q34539001-AE117F72-8E24-4738-94B4-54B6810476F3Q34552026-F29DE75F-1C8B-43C8-9A2B-F6E812A0BCB1Q34639437-15320EB8-482C-4006-A355-A69A352D7D94Q35087049-A412D1C8-D93D-4C72-B9B4-9158CEBC8E1FQ35093140-1FE57A13-6CEF-44F3-93E7-A35A10BDB064Q35152005-B2FA66D7-763E-4AA8-8EDE-603204FD1A1AQ35207995-21139E97-5A08-4DFD-9503-FCB0A0E65603Q35225398-89EA4367-FF7D-4819-9B84-9D8E76F951DAQ35328005-08216497-1FEC-4A17-87C1-92966E35D4F6Q35539874-D60596D0-0D56-44DF-A201-23DC0530A829Q35550950-E57A10E8-EF1A-4B72-AF5F-6DE1E7868A5FQ35755940-E1AC9959-8899-4CDA-8972-946292672093Q35782419-62B3FD04-3545-4FBF-A0B2-FD3B035242BEQ35898649-B0A13899-1BE7-4F15-AAF7-8B51F8D2AEFFQ35905134-C9DEDB2A-F1F4-4E49-81CA-E9377C07701DQ35989759-71F0ECCC-4CE5-48F0-B659-DFA2D1791392Q36070254-F051325A-0FC8-4704-B699-6E99CBB47EA3
P2860
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
The effects of combination the ...... results from the CombAT study.
@en
type
label
The effects of combination the ...... results from the CombAT study.
@en
prefLabel
The effects of combination the ...... results from the CombAT study.
@en
P2093
P1433
P1476
The effects of combination the ...... results from the CombAT study.
@en
P2093
Betsy B Morrill
Claus G Roehrborn
CombAT Study Group
Indrani Nandy
Jack Barkin
Kim Major-Walker
Paul Siami
R Paul Gagnier
Ronaldo Damião
P304
P356
10.1016/J.EURURO.2009.09.035
P407
P577
2009-09-19T00:00:00Z